These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 17199218)

  • 1. The HF epidemic: the need for new treatment strategies.
    Carson PE
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S32-4. PubMed ID: 17199218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological therapy of chronic heart failure in the elderly].
    Sabbadini G; Di Lenarda A; Metra M; Nodari S; Moretti M; Brentana L; Dei Cas L; Sinagra G
    Ital Heart J; 2004 Dec; 5 Suppl 10():37S-51S. PubMed ID: 15712511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL; Baker WL; White CM
    Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reassessing guidelines for heart failure.
    Drexler H; Wollert KC
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S28-33. PubMed ID: 15526240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the treatment of heart failure with a preserved ejection fraction.
    Das A; Abraham S; Deswal A
    Curr Opin Cardiol; 2008 May; 23(3):233-40. PubMed ID: 18382212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conclusions on the management of heart failure.
    Swedberg K
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S34-6. PubMed ID: 15526241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
    Shah NC; Pringle S; Struthers A
    J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):20-30. PubMed ID: 17083070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug treatment for chronic systolic heart failure.
    Mörike K; Sindermann JR
    Thorac Cardiovasc Surg; 2010 Feb; 58 Suppl 2():S170-2. PubMed ID: 20101534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chronic heart failure treatment in the year 2006].
    De Berrazueta Fernández JR
    An R Acad Nac Med (Madr); 2006; 123(3):617-30. PubMed ID: 17451101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations of current medical therapies for the treatment of heart failure.
    Miller LW
    Rev Cardiovasc Med; 2003; 4 Suppl 2():S21-9. PubMed ID: 12776010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ACE inhibitors, beta blockers, AT-1 antagonists in heart failure. Right dosage and combination].
    Fliri M
    MMW Fortschr Med; 2002 Nov; 144(48):38-43. PubMed ID: 12532542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.